Straight talk.
Hard topics.
Smart people.
Let's Talk
Series Introduction
Your host, Dr. Sue Wallace, CEO of Voximetry kicks off the Let’s Talk thought leader series by sharing her vision for listening, sharing, and community engagement to advance clinical RPT dosimetry and achieve a new standard of personalized cancer care.
Post-Administration Imaging of Radiotherapeutics?
In Part 1 of this series, Dr. Richard Wahl shares current practices and the evolving topic of post-administration imaging of radiotherapeutics to establish a baseline for disease state.
The Bexxar Experience: The Pros and Cons of On-Label Dosimetry
In Part 2 of this series, Dr. Wahl reflects upon the advent of theranostics and the advancements, obstacles and outlook for RPT dosimetry to advance personalized care for late-stage cancer patients.
test
The Digital Twin: Let’s make it a reality.
Research scientist, Julia Brosch-Lenz explains the benefits of developing a theranostics blueprint to model treatment options and outcomes and the need for global clinical data sharing to make the promise of the digital twin a reality.test
Do You Have a Defendable Position?
James Crowley and Dustin Osborne share their journey in developing a mature radiopharmaceutical therapy dosimetry program for the clinic and “why now?” is the question clinicians should be answering.test
Multi-Timepoint Imaging: They do come back.
The conversation with Crowley and Osborne continues as they discuss what’s best for the patient and what clinics can expect when establishing timepoint imaging protocols.
test
RPT Dosimetry Reimbursement: A clinical reality.
With established US reimbursement, James Crowley and Dustin Osborne discuss billing procedures for clinical RPT dosimetry and dispel common misconceptions related how billing procedures are managed.test
Managing RPT Workflows: Lessons learned.
In Part 4, Crowley and Osborne share how they have developed robust workflows for clinical RPT dosimetry and how their organizations and care teams have adopted new tools and procedures for standardization.
test
Finding Opportunity in RPT Uncertainty.
Stephen Graves and Rob Hobbs examine the nuances of therapies and differences of uncertainty in dose calculations for EBR and radiopharmaceuticals. Together they explore the realities and opportunities for certain uncertainty.
test
Another Pandora’s Box: Quality assurance & standardization.
The discussion between Stephen Graves and Rob Hobbs continues as they evaluate the obstacles, realities and benefits of RPT dosimetry adoption and perspectives to establish workflows that drive quality assurance and standardization.
test
Into the Great Unknown: Maximum tolerated activity.
As practicing radiation and nuclear medicine physicists, Graves and Hobbs ask what can be learned from radiation therapy in terms of normal tissue and tumor dose affect relationships and current limitations on normal organ dose.test
Accelerate Your Science!
Mike Maker of Flywheel.io explains how the automation and secure transfer of data can dramatically impact the efficient scale of clinical research and clinical therapy alike.test
Why do Drug Developers do so Many Trials “Down Under”?
The team from GenesisCare CRO, Jovana Milosevic and Boon Quan Lee, explain why Australia is a hot spot for radiopharmaceutical drug development and its regional advantages for clinical trials led by pharma and research organizations globally.test
Relevance of Traceability for Dosimetry.
International researcher and medical physicist Manuel Bardies shares over 35 years of experience in dosimetry and how standardization within the processes is being implemented to ensure that every clinic can offer the same high quality of treatment.
test
Do You Know Where Your Daughter Is?
Join radiochemist Reiner Hernandez, PhD to learn how radiopharmaceuticals for novel therapies are being developed and optimized and the “yin and yang” relationship between agents and radiobiological science for maximum efficacy.test
